Bessemer Group Inc. Acquires New Stake in Icon Plc (ICLR)
Bessemer Group Inc. acquired a new position in Icon Plc (NASDAQ:ICLR) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,380 shares of the medical research company’s stock, valued at approximately $267,000.
A number of other large investors have also added to or reduced their stakes in ICLR. SG Americas Securities LLC purchased a new position in Icon in the third quarter worth $148,000. Advisor Partners LLC purchased a new position in Icon in the fourth quarter worth $201,000. Commonwealth Equity Services Inc purchased a new position in Icon in the third quarter worth $208,000. Holderness Investments Co. purchased a new position in Icon in the third quarter worth $216,000. Finally, Murphy Capital Management Inc. purchased a new position in Icon in the third quarter worth $239,000. Hedge funds and other institutional investors own 89.66% of the company’s stock.
Shares of Icon Plc (ICLR) opened at $109.36 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90. The company has a market capitalization of $5,910.00, a price-to-earnings ratio of 21.23, a P/E/G ratio of 1.51 and a beta of 0.48. Icon Plc has a 52 week low of $76.46 and a 52 week high of $124.48.
ILLEGAL ACTIVITY NOTICE: “Bessemer Group Inc. Acquires New Stake in Icon Plc (ICLR)” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://theolympiareport.com/2018/02/14/bessemer-group-inc-acquires-new-stake-in-icon-plc-iclr.html.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.